High-grade Serous Ovarian Cancer Clinical Trial
Official title:
PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02307240 -
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT05062174 -
Breast Cancer BRCA1 Carriers: a Pilot Study
|
||
| Recruiting |
NCT05027828 -
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
|
||
| Completed |
NCT05188781 -
Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer
|
||
| Recruiting |
NCT05281471 -
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
|
Phase 3 |